{'fraction_non_alphanumeric': 0.026113671274961597, 'fraction_numerical': 0.007680491551459293, 'mean_word_length': 5.547738693467337, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Studies on the binding of [3H]flumazenil and [3H]sarmazenil in post‐mortem human brain

Two benzodiazepine analogues, [3H]flumazenil and [3H]sarmazenil, were used to study the GABAA/benzodiazepine receptor complex in human post‐mortem brain using in vitro receptor assays on homogenates and whole hemisphere autoradiography. Both radioligands bound in a saturable manner to single binding sites in the tissue preparations from any brain region. The highest levels of binding were found in the cortical regions and in cortex cerebelli. Both [3H]flumazenil and [3H]sarmazenil were excellent radioligands for autoradiography with high binding in cerebral and cerebellar cortex with no or very low binding in areas with white matter. The addition of a high concentration of flumazenil or clonazepam did not inhibit the binding of [3H]sarmazenil to granule cells in the cerebellum while the binding of [3H]flumazenil was abolished completely in all regions. The results show that with the two different radioligands, one an antagonist and one a partial inverse agonist, the binding pattern to GABAA/benzodiazepine receptor complex is approximately similar in most brain regions. The additional binding seen in the cerebellum with [3H]sarmazenil is suggested to be due to binding to an α6‐containing complex.